Immucell (ICCC) Accumulated Expenses (2010 - 2026)
Immucell's (ICCC) quarterly Accumulated Expenses came in at $1.0 million in Q4 2025, down 13.65% YoY from $1.2 million in Q4 2024, and up 5.63% on a QoQ basis from $977466.0 in Q3 2025.
Immucell (ICCC) Accumulated Expenses (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 14 years of Accumulated Expenses data on file, last reported at $1.0 million in Q4 2025.
- Quarterly Accumulated Expenses fell 13.65% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (down 13.65% YoY) and the FY2025 annual result came in at $1.0 million, down 13.65% from the prior year.
- Accumulated Expenses improved to $1.0 million in Q4 2025, from $977466.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.3 million in Q2 2024 to a low of $143872.0 in Q4 2022.
- A 5-year average of $704997.4 and a median of $766153.5 in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses sank 75.45% — and 2023, when it surged 555.44%.
- Tracing ICCC's Accumulated Expenses over 5 years: stood at $585939.0 in 2021, then slumped by 75.45% to $143872.0 in 2022, then surged by 555.44% to $942999.0 in 2023, then increased by 26.8% to $1.2 million in 2024, then fell by 13.65% to $1.0 million in 2025.
- The last three Accumulated Expenses figures came in at $1.0 million (Q4 2025), $977466.0 (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Mn |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 977,466.00 |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 782,390.00 |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 879,073.00 |
| Dec 31, 2023 | 942,999.00 |
| Sep 30, 2023 | 206,218.00 |
| Jun 30, 2023 | 963,765.00 |
| Mar 31, 2023 | 749,917.00 |
| Dec 31, 2022 | 143,872.00 |
| Sep 30, 2022 | 576,039.00 |
| Jun 30, 2022 | 664,023.00 |
| Mar 31, 2022 | 250,344.00 |
| Dec 31, 2021 | 585,939.00 |
| Sep 30, 2021 | 197,140.00 |
| Jun 30, 2021 | 192,593.00 |